Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis

References

1. 1.↵
   2. Spencer JI,
   3. Bell JS,
   4. DeLuca GC

   . Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry 2018;89:42–52 doi:10.1136/jnnp-2017-316011 pmid:28860328

   Abstract/FREE Full Text
2. 2.↵
   2. Rae-Grant AD,
   3. Wong C,
   4. Bernatowicz R, et al

   . Observations on the brain vasculature in multiple sclerosis: a historical perspective. Mult Scler Relat Disord 2014;3:156–62 doi:10.1016/j.msard.2013.08.005 pmid:25878003

   CrossRefPubMed
3. 3.↵
   2. Haider L,
   3. Zrzavy T,
   4. Hametner S, et al

   . The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016;139:807–15 doi:10.1093/brain/awv398 pmid:26912645

   CrossRefPubMed
4. 4.↵
   2. Desai RA,
   3. Davies AL,
   4. Tachrount M, et al

   . Cause and prevention of demyelination in a model multiple sclerosis lesion. Ann Neurol 2016;79:591–604 doi:10.1002/ana.24607 pmid:26814844

   CrossRefPubMed
5. 5.↵
   2. Marshall O,
   3. Lu H,
   4. Brisset JC, et al

   . Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol 2014;71:1275–81 doi:10.1001/jamaneurol.2014.1668 pmid:25133874

   CrossRefPubMed
6. 6.↵
   2. Marrie RA,
   3. Rudick R,
   4. Horwitz R, et al

   . Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041–47 doi:10.1212/WNL.0b013e3181d6b125 pmid:20350978

   Abstract/FREE Full Text
7. 7.↵
   2. Weinstock-Guttman B,
   3. Zivadinov R,
   4. Mahfooz N, et al

   . Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011;8:127 doi:10.1186/1742-2094-8-127 pmid:21970791

   CrossRefPubMed
8. 8.↵
   2. Weinstock-Guttman B,
   3. Zivadinov R,
   4. Horakova D, et al

   . Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013;84:1186–91 doi:10.1136/jnnp-2012-304740 pmid:23595944

   Abstract/FREE Full Text
9. 9.↵
   2. Kowalec K,
   3. McKay KA,
   4. Patten SB, et al

   ; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS). Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology 2017;89:2455–61 doi:10.1212/WNL.0000000000004716 pmid:29117961

   Abstract/FREE Full Text
10. 10.↵
    2. Kappus N,
    3. Weinstock-Guttman B,
    4. Hagemeier J, et al

    . Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016;87:181–87 doi:10.1136/jnnp-2014-310051 pmid:25722366

    Abstract/FREE Full Text
11. 11.↵
    2. Pichler A,
    3. Khalil M,
    4. Langkammer C, et al

    . The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis. Mult Scler 2017 Oct 1. [Epub ahead of print] doi:10.1177/1352458517736149 pmid:29027843

    CrossRefPubMed
12. 12.↵
    2. Christiansen CF

    . Risk of vascular disease in patients with multiple sclerosis: a review. Neurol Res 2012;34:746–53 doi:10.1179/1743132812Y.0000000051 pmid:22709796

    CrossRefPubMed
13. 13.↵
    2. Marcotti S,
    3. Marchetti L,
    4. Cecconi P, et al

    . An anatomy-based lumped parameter model of cerebrospinal venous circulation: can an extracranial anatomical change impact intracranial hemodynamics? BMC Neurol 2015;15:95 doi:10.1186/s12883-015-0352-y pmid:26099795

    CrossRefPubMed
14. 14.↵
    2. Zamboni P,
    3. Galeotti R,
    4. Menegatti E, et al

    . Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:392–99 doi:10.1136/jnnp.2008.157164 pmid:19060024

    Abstract/FREE Full Text
15. 15.↵
    2. Zivadinov R,
    3. Lopez-Soriano A,
    4. Weinstock-Guttman B, et al

    . Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology 2011;258:562–70 doi:10.1148/radiol.10101387 pmid:21177394

    CrossRefPubMed
16. 16.↵
    2. Sethi SK,
    3. Utriainen DT,
    4. Daugherty AM, et al

    . Jugular venous flow abnormalities in multiple sclerosis patients compared to normal controls. J Neuroimaging 2015;25:600–07 doi:10.1111/jon.12183 pmid:25316522

    CrossRefPubMed
17. 17.↵
    2. Belov P,
    3. Jakimovski D,
    4. Krawiecki J, et al

    . Lower arterial cross-sectional area of carotid and vertebral arteries and higher frequency of secondary neck vessels are associated with multiple sclerosis. AJNR Am J Neuroradiol 2018;39:123–30 doi:10.3174/ajnr.A5469 pmid:29217748

    Abstract/FREE Full Text
18. 18.↵
    2. Zivadinov R,
    3. Ramasamy DP,
    4. Vaneckova M, et al

    . Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: a retrospective, pilot, observational longitudinal study. Mult Scler 2017;23:1336–45 doi:10.1177/1352458516678083 pmid:27811339

    CrossRefPubMed
19. 19.↵
    2. Zivadinov R,
    3. Ramasamy DP,
    4. Benedict RR, et al

    . Cerebral microbleeds in multiple sclerosis evaluated on susceptibility-weighted images and quantitative susceptibility maps: a case-control study. Radiology 2016;281:884–95 doi:10.1148/radiol.2016160060 pmid:27308776

    CrossRefPubMed
20. 20.↵
    2. Lublin FD,
    3. Reingold SC

    . Defining the clinical course of multiple sclerosis: results of an international survey—National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11 doi:10.1212/WNL.46.4.907 pmid:8780061

    Abstract/FREE Full Text
21. 21.↵
    2. Laganà MM,
    3. Pelizzari L,
    4. Scaccianoce E, et al

    . Assessment of internal jugular vein size in healthy subjects with magnetic resonance and semiautomatic processing. Behav Neurol 2016;2016:9717210 doi:10.1155/2016/9717210 pmid:27034585

    CrossRefPubMed
22. 22.↵
    2. Pelizzari L,
    3. Laganà MM,
    4. Jakimovski D, et al

    . Neck vessel cross-sectional area measured with MRI: scan-rescan reproducibility for longitudinal evaluations. J Neuroimaging 2018;28:48–56 doi:10.1111/jon.12488 pmid:29205670

    CrossRefPubMed
23. 23.↵
    2. Zivadinov R,
    3. Weinstock-Guttman B,
    4. Hashmi K, et al

    . Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009;73:504–10 doi:10.1212/WNL.0b013e3181b2a706 pmid:19687451

    Abstract/FREE Full Text
24. 24.↵
    2. Yuksel B,
    3. Koc P,
    4. Kurtulus F, et al

    . Is multiple sclerosis a risk factor for atherosclerosis? Multiple Sclerosis Journal: Sage Publication LTD, London, England; 2016:455–455
25. 25.↵
    2. Li J,
    3. Wang W,
    4. Han L, et al

    . Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model. Acta Biochim Biophys Sin (Shanghai) 2017;49:149–58 doi:10.1093/abbs/gmw128 pmid:28069582

    CrossRefPubMed
26. 26.↵
    2. Hautecoeur P,
    3. Forzy G,
    4. Gallois P, et al

    . Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 1997;97:240–43 pmid:9478261

    PubMedWeb of Science
27. 27.↵
    2. Dawson J,
    3. Miltz W,
    4. Mir AK, et al

    . Targeting monocyte chemoattractant protein-1 signaling in disease. Expert Opin Ther Targets 2003;7:35–48 doi:10.1517/14728222.7.1.35 pmid:12556201

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Damotte V,
    3. Guillot-Noel L,
    4. Patsopoulos NA, et al

    ; International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2. A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes Immun 2014;15:126–32 doi:10.1038/gene.2013.70 pmid:24430173

    CrossRefPubMed
29. 29.↵
    2. Chironi GN,
    3. Boulanger CM,
    4. Simon A, et al

    . Endothelial microparticles in diseases. Cell Tissue Res 2009;335:143–51 doi:10.1007/s00441-008-0710-9 pmid:18989704

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Orekhov AN,
    3. Sobenin IA

    . Modified lipoproteins as biomarkers of atherosclerosis. Front Biosci (Landmark Ed) 2018;23:1422–44 doi:10.2741/4653 pmid:29293443

    CrossRefPubMed
31. 31.↵
    2. Uher T,
    3. Fellows K,
    4. Horakova D, et al

    . Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. J Lipid Res 2017;58:403–11 doi:10.1194/jlr.M072751 pmid:27923871

    Abstract/FREE Full Text
32. 32.↵
    2. Debernard L,
    3. Melzer TR,
    4. Van Stockum S, et al

    . Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:544–51 doi:10.1136/jnnp-2013-305612 pmid:24039024

    Abstract/FREE Full Text
33. 33.↵
    2. Adhya S,
    3. Johnson G,
    4. Herbert J, et al

    . Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 2006;33:1029–35 doi:10.1016/j.neuroimage.2006.08.008 pmid:16996280

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Lapointe E,
    3. Li DK,
    4. Traboulsee AL, et al

    . What have we learned from perfusion MRI in multiple sclerosis? AJNR Am J Neuroradiol 2018;39:994–1000 doi:10.3174/ajnr.A5504 pmid:29301779

    Abstract/FREE Full Text
35. 35.↵
    2. Inglese M,
    3. Park SJ,
    4. Johnson G, et al

    . Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 2007;64:196–202 doi:10.1001/archneur.64.2.196 pmid:17296835

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Cocozza S,
    3. Canna A,
    4. Lanzillo R, et al

    . Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study. Brit J Radiol 2016 Jun 27. [Epub ahead of print] doi:10.1259/bjr.20160321 pmid:7282838

    CrossRefPubMed
37. 37.↵
    2. Zamboni P,
    3. Tesio L,
    4. Galimberti S, et al

    ; Brave Dreams Research Group. Efficacy and safety of extracranial vein angioplasty in multiple sclerosis: a randomized clinical trial. JAMA Neurol 2018;75:35–43 doi:10.1001/jamaneurol.2017.3825 pmid:29150995

    CrossRefPubMed
38. 38.↵
    2. Louveau A,
    3. Da Mesquita S,
    4. Kipnis J

    . Lymphatics in neurological disorders: a neuro-lympho-vascular component of multiple sclerosis and Alzheimer's disease? Neuron 2016;91:957–73 doi:10.1016/j.neuron.2016.08.027 pmid:27608759

    CrossRefPubMed
39. 39.↵
    2. Healy BC,
    3. Ali EN,
    4. Guttmann CR, et al

    . Smoking and disease progression in multiple sclerosis. Arch Neurol 2009;66:858–64 pmid:19597087

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Kavak KS,
    3. Teter BE,
    4. Hagemeier J, et al

    . Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler 2015;21:858–65 doi:10.1177/1352458514555787 pmid:25392327

    CrossRefPubMed
41. 41.↵
    2. Lindsay AC,
    3. Biasiolli L,
    4. Knight S, et al

    . Non-invasive imaging of carotid arterial restenosis using 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reason 2014;16:5 doi:10.1186/1532-429X-16-5 pmid:24400841

    CrossRefPubMed